Research and Clinical Trials

Brief Description  
This study is a randomized trial that will compare progression free survival between Regorafenib + FOLFORI chemotherapy versus placebo + FOLFORI in patients with metastatic colorectal cancer and KRAS or BRAF mutant disease previously treated with a FOLFOX regimen.
Who may be Eligible  
Second-Line therapy in patients with K-RAS or BRAF mutant with metastatic colorectal cancer.
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Address:1100 S. Tryon Street Suite 220 Charlotte, NC 28203